Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Meet Tom Butera

Key Takeaway: The article introduces Dr. Tom Butera, the CEO of Volition Veterinary, highlighting his career motivations and aspirations for the company. It emphasizes his leadership role and the advancements in veterinary cancer testing, particularly the Nu.Q® Vet Cancer Test. The article also mentions upcoming milestones related to the test's publication.
Price reaction · baseline $22 (2024-01-24 close) · hit pre-market · 8 other VNRX headline(s) in the window, move may be shared
day 0 close
-5.5%
day 1
-2.7%
day 3 · peak
-8.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Tom Butera's leadership is promising for Volition Veterinary.
  • The company is advancing veterinary cancer testing technology.
  • There are significant milestones expected with the Nu.Q® Vet Cancer Test.

Full Press Release Details

Meet Volition Veterinary CEO, Dr. Tom Butera. Watch his short video to learn about Tom’s career, his motivation behind joining Volition Veterinary, being the leader of Volition Veterinary, his team, his hopes for the future, and more.

Related Articles

• Press Releases Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment
• Press Releases Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

Who is Dr. Tom Butera?

Dr. Tom Butera is the CEO of Volition Veterinary, leading advancements in veterinary care.

What is the Nu.Q® Vet Cancer Test?

The Nu.Q® Vet Cancer Test is a veterinary cancer testing technology developed by Volition.

What milestone is expected for the Nu.Q® Vet Cancer Test?

The publication of a related study is expected to unlock a $5 million milestone payment.

What are Dr. Butera's hopes for Volition Veterinary?

Dr. Butera aims to advance veterinary cancer testing and lead a successful team.

Last updated: Jan 25, 2024